1,384 results match your criteria Hodgkin Disease Thoracic


Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression.

Hum Cell 2022 Jul 8;35(4):1234-1247. Epub 2022 Jun 8.

Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, Hebei, China.

Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) globally, featuring heterogeneous clinical phenotypes and altered molecular manifestations. The long non-coding ribose nucleic acids (lncRNAs) play crucial roles in the diagnosis, treatment, and prognosis of DLBCL, requiring the exploration of complex functions and mechanisms. In this study, the expression of lncRNA TRIM52-AS1 in DLBCL tissues from the Cancer Genome Atlas (TCGA) database was initially analyzed and correlated to the data from collected clinical samples. Read More

View Article and Full-Text PDF

"Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides".

Front Cell Infect Microbiol 2022 17;12:850509. Epub 2022 May 17.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, United States.

Cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma, is thought to arise from mature tissue-resident memory T cells. The most common subtypes include Mycosis Fungoides and Sezary Syndrome. The role of skin microbiota remains unclear in the symptom manifestation of MF. Read More

View Article and Full-Text PDF

Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study.

BMC Pulm Med 2022 Apr 28;22(1):165. Epub 2022 Apr 28.

Manchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4QL, UK.

Background: Many Hodgkin lymphoma (HL) survivors are at increased risk of subsequent malignant neoplasms (SMN), including lung cancer, due to previous treatment for HL. Lung cancer screening (LCS) detects early-stage lung cancers in ever smokers but HL survivors without a heavy smoking history are ineligible for screening. There is a rationale to develop a targeted LCS. Read More

View Article and Full-Text PDF

Hodgkin Lymphoma in Children Under 5 Years: Do They Behave Differently?

J Pediatr Hematol Oncol 2022 05 16;44(4):186-190. Epub 2022 Mar 16.

Department of Pediatrics, Kalawati Saran Children's Hospital.

The median age of presentation for Hodgkin lymphoma (HL) is lower in developing countries with a higher proportion under 5 years of age possibly attributable to the high prevalence of Epstein-Barr virus-driven disease. It is unclear whether the clinical presentation and outcomes of this cohort are different with concern regarding late effects being most pronounced in this age group. We report the outcome of children under 5 years of age enrolled in the InPOG-HL-15-01, the first multicentric collaborative study for newly diagnosed children and adolescents with HL from India. Read More

View Article and Full-Text PDF

Unrecognized thoracic radiotherapy toxicity: A review of literature.

Cancer Radiother 2022 Jun 10;26(4):616-621. Epub 2022 Feb 10.

LaTIM, INSERM, UMR 1101, University of Brest, 29200, Brest, France.

Radiotherapy remains an important treatment modality for patients with chest malignancies; this is particularly true in patients with breast cancer and Hodgkin lymphoma as well as lung, esophageal, and other mediastinal tumors. More than half of patients with these conditions receive radiotherapy at some point. With the development of new treatment modalities, we are witnessing an improvement of overall survival requiring carefully watching of acute and chronic toxicity of radiation therapy. Read More

View Article and Full-Text PDF

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

J Clin Oncol 2022 04 6;40(10):1091-1101. Epub 2022 Jan 6.

Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France.

Purpose: The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results. Read More

View Article and Full-Text PDF

Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.

Int J Radiat Oncol Biol Phys 2022 03 9;112(4):913-925. Epub 2021 Nov 9.

Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Purpose: In some patients with Hodgkin lymphoma (HL), proton beam therapy (PBT) may reduce the risk of radiation-related cardiovascular disease (CVD) and second cancers (SC) compared with photon radiation therapy (RT). Our aim was to identify patients who benefit the most from PBT in terms of predicted 30-year absolute mortality risks (AMR) from CVD and SC, taking into account individual background, chemotherapy, radiation, and smoking-related risks.

Methods And Materials: Eighty patients with supradiaphragmatic HL treated with PBT between 2015 and 2019 were replanned using optimal photon RT. Read More

View Article and Full-Text PDF

Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations.

Front Cell Dev Biol 2021 3;9:661272. Epub 2021 Aug 3.

Sorbonne University, INSERM, Research Unit on Cardiovascular and Metabolic Disease UMR ICAN, Department of Endocrine Biochemistry and Oncology, AP-HP, Hôpital Pitié Salpêtrière, Paris, France.

Cell-free DNA (cfDNA) analysis is a minimally invasive method that can be used to detect genomic abnormalities by directly testing a blood sample. This method is particularly useful for immunosuppressed patients, who are at high risk of complications from tissue biopsy. The cfDNA tumor fraction (TF) varies greatly across cancer type and between patients. Read More

View Article and Full-Text PDF

A 51-Year-Old Man With a Large Posterior Mediastinal Mass.

Chest 2021 10;160(4):e357-e363

Department of Medicine, Division of Pulmonary & Critical Care Medicine, Albany Medical College, Albany, NY.

Case Presentation: A 51-year-old White male never-smoker presented with intermittent cough and progressive dyspnea. His symptoms started after an exposure to bat guano while cleaning his attic approximately 9 months earlier. He has received several courses of antibiotic and corticosteroid for these symptoms, with short-term relief. Read More

View Article and Full-Text PDF
October 2021

Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.

JACC CardioOncol 2021 Sep 21;3(3):360-380. Epub 2021 Sep 21.

Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA.

Radiation therapy is a cornerstone of cancer therapy, with >50% of patients undergoing therapeutic radiation. As a result of widespread use and improved survival, there is increasing focus on the potential long-term effects of ionizing radiation, especially cardiovascular toxicity. Radiation therapy can lead to atherosclerosis of the vasculature as well as valvular, myocardial, and pericardial dysfunction. Read More

View Article and Full-Text PDF
September 2021

Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification.

JACC CardioOncol 2021 Sep 21;3(3):343-359. Epub 2021 Sep 21.

Cardio-Oncology Center of Excellence, Washington University, St. Louis, Missouri, USA.

Radiation therapy is an important component of cancer therapy for many malignancies. With improvements in cardiac-sparing techniques, radiation-induced cardiac dysfunction has decreased but remains a continued concern. In this review, we provide an overview of the evolution of radiotherapy techniques in thoracic cancers and associated reductions in cardiac risk. Read More

View Article and Full-Text PDF
September 2021

Synchronous Recurrence of Metachronous Lung Cancer and Hodgkin Lymphoma Within an Axillary Lymph Node Isolated on 18F-FDG PET/CT.

Clin Nucl Med 2022 Mar;47(3):e262-e264

Abstract: An 82-year-old man with a background of non-Hodgkin lymphoma in remission, resected left lower lobe adenocarcinoma (stage IA), and resected cutaneous melanoma of the left forearm more than 5 years prior presented with cerebral metastatic disease. Excision biopsy confirmed adenocarcinoma of lung origin. Further evaluation with 18F-FDG PET/CT demonstrated FDG-avid disease in the right thorax, axilla, and lower neck and isolated cutaneous uptake in the right forearm. Read More

View Article and Full-Text PDF

Mediastinal Nodular Lymphocyte Predominant Hodgkin Lymphoma Achieved by Endoscopic Transesophageal Cryobiopsy.

Respiration 2022;101(2):190-194. Epub 2021 Sep 1.

Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.

Guidelines have recommended endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound-guided fine-needle aspiration biopsy as initial sampling approaches of mediastinal lymph nodes for lung cancer staging. However, the small sample volume might restrict the diagnostic utility of needle aspiration in certain mediastinal diseases. We have recently shown that transbronchial mediastinal cryobiopsy, which is capable of providing larger amounts of intact tissue, improves diagnostic yield in rare tumors and benign diseases compared to EBUS-TBNA. Read More

View Article and Full-Text PDF

Primary B-cell Lymphoma of the Thoracic Spine: A Rare Cause of Spinal Cord Compression.

Cureus 2021 Jul 24;13(7):e16608. Epub 2021 Jul 24.

Department of Orthopedics, Traumatology, and Rehabilitation, International Islamic University Malaysia, Kuantan, MYS.

Primary non-Hodgkin lymphoma arising from the spine is exceedingly rare. Spinal cord compression can be the first presentation of a patient with primary spinal non-Hodgkin lymphoma. Due to its rarity and vague clinical presentation, the diagnosis can be confused with tuberculosis of the spine, a more common disease in this country. Read More

View Article and Full-Text PDF

Spinal cord compression as tumor onset: an unusual case report of Hodgkin lymphoma in a teenager.

BMC Pediatr 2021 08 24;21(1):358. Epub 2021 Aug 24.

Unit of Pediatric Hematology Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico "G. Rodolico", University of Catania, Via Santa Sofia 78, Catania, Italy.

Background: Spinal cord compression (SCC) is an uncommon, severe complication of Hodgkin lymphoma (HL), occurring in 0.2% of cases at the onset and in 6% during disease progression. We present a teenager with SCC with clinical onset of HL; her pre-existing neurological abnormalities covered the presence of an epidural mass, which could have misled us. Read More

View Article and Full-Text PDF

How I Diagnose Primary Mediastinal (Thymic) Large B-Cell Lymphoma.

Am J Clin Pathol 2021 Sep;156(4):497-512

Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Objectives: Primary mediastinal (thymic) large B-cell lymphoma (PMBL) is an uncommon large B-cell neoplasm recognized by the World Health Organization as a distinct entity on the basis of its unique clinical features, histogenesis, phenotype, and pathogenetic mechanisms. The diagnosis of PMBL can be challenging because of features that may overlap with other (Hodgkin and non-Hodgkin) lymphoma types. This review describes our approach to the diagnosis of PMBL. Read More

View Article and Full-Text PDF
September 2021

Elevated resting heart rate is a marker of subclinical left ventricular dysfunction in hodgkin lymphoma survivors.

Int J Cardiol Heart Vasc 2021 Aug 25;35:100830. Epub 2021 Jun 25.

Department of Cardiology, Heart Lung Center, Leiden University Medical Centre, Leiden, the Netherlands.

Background: Thoracic irradiation is one of the cornerstones of Hodgkin lymphoma (HL) treatment, which contributes to high rates of long-term survivorship, but begets a life-long increased risk of heart disease including heart failure. At the cardio-oncology (CO) clinic, persistent sinus tachycardia or elevated resting heart rate (RHR) is frequently observed in these patients. The aim of this study was to evaluate the relation between RHR and left ventricular (LV) dysfunction. Read More

View Article and Full-Text PDF

Primary Hodgkin lymphoma of the lung arising with hemoptysis and pulmonary consolidation: a case report.

Monaldi Arch Chest Dis 2021 Jun 10;91(4). Epub 2021 Jun 10.

Division of Thoracic Surgery, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar (VR).

Classic Hodgkin lymphomas are neoplasms originating from lymphoid tissue. Primary extra-nodal classic Hodgkin lymphoma (PE-cHL) of the lung is rare. A 37-years-old Caucasian male was referred to our hospital for recurrent episodes of hemoptysis, cough and bronchitis. Read More

View Article and Full-Text PDF

Pulmonary Hypertension in Patients with Common Variable Immunodeficiency.

J Clin Immunol 2021 10 10;41(7):1549-1562. Epub 2021 Jun 10.

Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.

Purpose: Common variable immunodeficiency (CVID) is known to cause infectious, inflammatory, and autoimmune manifestations. Pulmonary hypertension (PH) is an unusual complication of CVID with largely unknown characteristics and mechanisms.

Methods: We report the clinical, functional, hemodynamics, radiologic and histologic characteristics, and outcomes of CVID-associated PH patients from the French PH Network. Read More

View Article and Full-Text PDF
October 2021

Mediastinal Lymphoproliferative Disorders.

Adv Anat Pathol 2021 Sep;28(5):307-334

Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR.

Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. Read More

View Article and Full-Text PDF
September 2021

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.

Cells 2021 05 10;10(5). Epub 2021 May 10.

Mater Research Institute, University of Queensland, Brisbane, QLD 4102, Australia.

The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology. This is highlighted by the success of agents that interrupt PD-1 mediated immune suppression in a range of cancers. Read More

View Article and Full-Text PDF

High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Ups J Med Sci 2021 15;126. Epub 2021 Feb 15.

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Background: Hodgkin lymphoma (HL) patients have a good prognosis after adequate treatment. Previous treatment with mantle field irradiation has been accompanied by an increased long-term risk of cardiovascular disease (CVD). This study identified co-morbidity factors for the development of cardiovascular side effects and initiated an intervention study aimed to decrease morbidity and mortality of CVD in HL survivors. Read More

View Article and Full-Text PDF
January 2022

Primary esophageal non-Hodgkin's lymphoma: demographics, clinical characteristics, histopathologic types, and survival in 179 patients from the SEER program and systematic review of the literature.

Esophagus 2021 10 20;18(4):734-742. Epub 2021 Apr 20.

Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, Colombia.

Background: The most frequent site for the extranodal appearance of primary non-Hodgkin's lymphomas (NHL) is the gastrointestinal (G.I.) tract. Read More

View Article and Full-Text PDF
October 2021

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.

Theranostics 2021 4;11(10):4699-4709. Epub 2021 Mar 4.

Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.

The onset of cytokine release syndrome (CRS) and persistence of anti-CD19 chimeric antigen receptor T (CAR-T) cells after infusion correlate with clinical responsiveness. However, there are no known baseline biomarkers that can predict the prognosis of patients with B-lineage non-Hodgkin lymphoma (B-NHL). The aim of this study was to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies. Read More

View Article and Full-Text PDF

Primary Hepatic Lymphoma After Lung Transplantation: A Report of 2 Cases.

Transplant Proc 2021 Mar 30;53(2):692-695. Epub 2021 Jan 30.

Digestive and Endocrine Surgery, Nouvel Hopital Civil, University of Strasbourg, Strasbourg, France; IHU Strasbourg, Institute of Image-Guided Surgery, Strasbourg, France; IRCAD, Research Institute Against Digestive Cancer, Strasbourg, France. Electronic address:

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the posttransplant setting. Treatment is based on chemotherapy; surgery is still debated and should be performed in very select cases.

Methods: We observed 2 patients out of 300 who underwent lung transplantation in the Nouvel Hopital Civil between 2013 and 2019 with primary hepatic lymphoma. Read More

View Article and Full-Text PDF

Primary Pulmonary B-Cell Lymphoma: A Review and Update.

Cancers (Basel) 2021 Jan 22;13(3). Epub 2021 Jan 22.

Pathology Unit, Azienda Ospedaliera S. Maria di Terni, University of Perugia, 05100 Terni, Italy.

Primary pulmonary B-cell lymphomas (PP-BCLs) comprise a group of extranodal non-Hodgkin lymphomas of B-cell origin, which primarily affect the lung without evidence of extrapulmonary disease at the time of diagnosis and up to 3 months afterwards. Primary lymphoid proliferations of the lung are most often of B-cell lineage, and include three major entities with different clinical, morphological, and molecular features: primary pulmonary marginal zone lymphoma of mucosa-associated lymphoid tissue (PP-MZL, or MALT lymphoma), primary pulmonary diffuse large B cell lymphoma (PP-DLBCL), and lymphomatoid granulomatosis (LYG). Less common entities include primary effusion B-cell lymphoma (PEL) and intravascular large B cell lymphoma (IVLBCL). Read More

View Article and Full-Text PDF
January 2021

Radio-induced esophageal motility disorders: An unrecognized diagnosis.

Cancer Radiother 2021 May 14;25(3):249-253. Epub 2021 Jan 14.

Service de radiothérapie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, Aix-Marseille Université, Chemin des Bourrelys, Marseille , France.

Purpose: Esophageal motility disorders (EMD) after cervical or thoracic radiation therapy (RT) may represent a late impairment and appear under-diagnosed. This study aimed to assess the prevalence of EMD, diagnosed by high-resolution esophageal manometry (HREM) after cervical or thoracic RT. In this retrospective, single-centre study, all patients whom received cervical or thoracic RT and underwent HREM were eligible. Read More

View Article and Full-Text PDF

Multiple lung lesions in a 13-year-old girl with classical nodular sclerosis Hodgkin Lymphoma.

Int J Hematol 2021 Mar 1;113(3):318-319. Epub 2021 Jan 1.

Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.

View Article and Full-Text PDF

Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.

Biochem Biophys Res Commun 2021 01 13;534:773-779. Epub 2020 Nov 13.

Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address:

Mantle Cell Lymphoma (MCL) is a non-Hodgkin lymphoma with a median survival rate of five years. Standard treatment with high-dose chemotherapy plus rituximab (anti-CD20 antibody) has extended overall survival although, the disease remains incurable. Histone deacetylases (HDAC) are a family of enzymes that regulate multiple proteins and cellular pathways through post-translational modification. Read More

View Article and Full-Text PDF
January 2021